Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND007 in Chronic Obstructive Pulmonary Disease (COPD)
NCT07355868Phase 1Recruiting
- Sponsor
- Regend Therapeutics
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of REGEND-007 in chronic obstructive pulmonary disease (COPD), sponsored by Regend Therapeutics. Primary endpoint: Incidence and severity of drug-related adverse events at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
REGEND-007
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07355868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355868.